Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

PRRT Moves Needle Forward in NETs, But Unmet Needs Remain

March 12th 2019

Michael Morse, MD, FACP, MHS, highlights the importance of peptide receptor radionuclide therapy in the management of patients with neuroendocrine tumors and identifies significant unmet needs that will need to be addressed in order to continue advancement in the space.

Adjuvant Treatment Strategy Shows Promise in Pancreatic Cancer

March 11th 2019

Autumn McRee, MD, highlights promising adjuvant/neoadjuvant strategies under investigation in the pancreatic cancer space and stresses the importance of using a multidisciplinary treatment approach to improve patient outcomes.

Expert Highlights Evidence-Based Decision-Making in mCRC

March 11th 2019

Michael S. Lee, MD, sheds light on the treatment options available in the metastatic colorectal cancer space and highlights strategies poised to improve patient outcomes.

Emerging Agents May Fill Therapeutic Gap in Metastatic Pancreatic Cancer

March 10th 2019

Niharika B. Mettu, MD, PhD, discusses frontline approaches, maintenance therapy, sequencing strategies, and emerging agents for patients with newly diagnosed metastatic pancreatic cancer.

Dr. Jiang on the Future of Immunotherapy in Microsatellite Stable Colorectal Cancer

March 9th 2019

Yixing Jiang, BM, PhD, associate professor of medicine, director, Gastrointestinal Medical Oncology Marlene Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, discusses the future of immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Strickler Stresses Continued Focus on Molecular Subtypes in mCRC

March 9th 2019

John Strickler, MD, highlights important data in the metastatic colorectal cancer space and challenges that remain for oncologists working in the field.

The Debate Over Early Screening for Pancreatic Cancer Continues

March 8th 2019

Higher costs associated with advanced stage pancreatic cancer, are potentially avoidable with screening and earlier treatment. However, the US Preventive Services Task Force in an ongoing draft review has reaffirmed its stance against screening in asymptomatic individuals.

Dr. Mettu on the Potential of CPI-613 in Metastatic Pancreatic Cancer

March 8th 2019

Niharika B. Mettu, MD, PhD, assistant professor medicine, Duke Cancer Institute, discusses the potential of CPI-613 in the treatment of patients with metastatic pancreatic cancer.

Higher Incidence, New Therapies Add to Cost of Treating Advanced Pancreatic Cancer

March 7th 2019

Pancreatic cancer is one of the few cancers that is on the rise, and this means that the overall cost of treating this disease is also climbing.

Dr. Weinberg on Broad Molecular Profiling in GI Cancers

March 7th 2019

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the importance of broad molecular profiling in patients with gastrointestinal cancers.

Gastrointestinal Cancer Research Abounds in Washington, DC

March 6th 2019

George P. Kim, MD, discusses areas of active investigation in the Washington, DC, area.

Pivotal Trials Lead to Significant Implications in Gastric/GEJ Cancer

March 6th 2019

Timothy L. Cannon, MD, discusses how pivotal clinical trials have impacted the gastric cancer treatment landscape.

Expert Discusses Frontline Standards, Dosing, and Novel Agents in Pancreatic Cancer

March 6th 2019

Benjamin Weinberg, MD, discusses frontline standards of care in metastatic pancreatic cancer and highlights emerging agents targeting the stroma.

Following Encouraging Therapeutic Advances, Focus in NETs Turns to Sequencing

March 6th 2019

Ana Maria Cristina De Jesus-Acosta, MD, discusses somatostatin analogs and peptide receptor radionucleotide therapy, and spoke to the discussion regarding the optimal sequence of therapy in patients with neuroendocrine tumors.

Dr. Marshall on Personalized Chemotherapy in CRC

March 5th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses personalized chemotherapy in the treatment of patients with colorectal cancer.

HCC Armamentarium Expands, With Promising Agents on the Horizon

March 5th 2019

Aiwu Ruth He, MD, PhD, discusses the newly crowded treatment landscape of hepatocellular carcinoma and highlights next steps for research.

Management of Metastatic CRC Rooted in Molecular Subsets

March 5th 2019

John L. Marshall, MD, discusses the current and future scope of metastatic colorectal cancer.

Dr. Katz on Preoperative Chemoradiation in Localized Pancreatic Cancer

March 5th 2019

Matthew H.G. Katz, MD, FACS, associate professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses preoperative chemoradiation for the treatment of patients with localized pancreatic cancer.

EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications

March 5th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.

Immunotherapy, Chemo Approaches Continue to Build in CRC and Pancreatic Cancer

March 5th 2019

Douglas A. Nelson, MD, discusses key advances made in the treatment of patients with colorectal cancer and pancreatic cancer, and sheds light on remaining challenges in these paradigms.